CADTH Reimbursement Review Pembrolizumab (Keytruda) - Sponsor: Merck Canada Inc. Therapeutic area: Persistent, recurrent, or metastatic cervical cancer

If your institution is a member, please log into Canada Commons from a link provided by your institution. This typically involves logging in via a menu managed by your library.

Accessing this content requires a membership

If your institution is a member, please log into Canada Commons from a link provided by your institution. This typically involves logging in via a menu managed by your library.